Xenetic Biosciences, Inc. (XBIO)
| Market Cap | 4.71M -43.3% |
| Revenue (ttm) | 3.26M +33.3% |
| Net Income | -2.48M |
| EPS | -1.19 |
| Shares Out | 2.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,378 |
| Open | 2.090 |
| Previous Close | 2.100 |
| Day's Range | 1.885 - 2.100 |
| 52-Week Range | 1.870 - 5.280 |
| Beta | 2.20 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company’s product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the tr... [Read more]
Financial Performance
In 2025, Xenetic Biosciences's revenue was $2.98 million, an increase of 19.04% compared to the previous year's $2.50 million. Losses were -$2.68 million, -32.31% less than in 2024.
Financial StatementsNews
Xenetic, PeriNess announce first patient dosed in DNase with CAR T cells study
Xenetic (XBIO) Biosciences announced that its collaboration partner, PeriNess, has informed the Company that the first patient has been dosed in an investigator-initiated clinical study evaluating sys...
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center Initial...
Xenetic Biosciences Transcript: M&A announcement
A share exchange will combine two companies with complementary NET-targeting technologies, creating a unified pipeline across four clinical-stage programs and aiming for leadership in NET therapeutics. The deal is expected to close in Q4 2026, with a European market launch targeted for 2028.
Xenetic Biosciences Press release: M&A announcement
Xenetic Biosciences issued a press release on September 16, 2026, disclosing material business information to investors.
Xenetic Biosciences Slides: M&A announcement
Xenetic Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 16, 2026.
Xenetic, Santerus enter definitive share exchange agreement
Xenetic (XBIO) Biosciences and Santersus announced that they have entered into a definitive share exchange agreement pursuant to which Xenetic will, subject to stockholder approval, acquire all of the...
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune...
Xenetic Biosciences Slides: Investor presentation
Xenetic Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategy Ongoing generation of translational data designed to support future clinical development and de...
Xenetic Biosciences Quarterly report: Q2 2026
Xenetic Biosciences has published its Q2 2026 quarterly earnings report on August 6, 2026.
Xenetic Biosciences Earnings release: Q2 2026
Xenetic Biosciences released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Xenetic partner PeriNess receives Israeli MOH approval for DNase I study
Xenetic (XBIO) Biosciences announced that its collaboration partner, PeriNess, has informed the Company that it received formal approval from the Israeli Ministry of Health and the respective Institut...
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion Company reported strong...
Xenetic announces preclinical data on DNase I at ASCO
Xenetic (XBIO) Biosciences announced positive preclinical data will be presented at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting demonstrating that DNase I significantly enhanc...
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to...
Xenetic Biosciences Slides: Investor presentation
Xenetic Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical development Strengthened financial profile with continued royalty rev...
Xenetic Biosciences Quarterly report: Q1 2026
Xenetic Biosciences has published its Q1 2026 quarterly earnings report on May 12, 2026.
Xenetic Biosciences Earnings release: Q1 2026
Xenetic Biosciences released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology te...
Xenetic Biosciences Slides: Corporate presentation
Xenetic Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on April 16, 2026.
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers Strategic focus on investigator-initiated exploratory studies and institut...
Xenetic Biosciences Earnings release: Q4 2025
Xenetic Biosciences released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Xenetic Biosciences Annual report: Q4 2025
Xenetic Biosciences has published its Q4 2025 annual report on March 12, 2026.
Xenetic Biosciences Transcript: AGM 2025
The meeting was called to order with auditors and legal counsel present, but a quorum was not reached, preventing any business from being conducted. The board will set a new date for the adjourned meeting.